| Rivaroxaban with or without aspirin in stable cardiovascular disease JW Eikelboom, SJ Connolly, J Bosch, GR Dagenais, RG Hart, ... New England Journal of Medicine 377 (14), 1319-1330, 2017 | 2096 | 2017 |
| EUROASPIRE IV: A European Society of Cardiology survey on the lifestyle, risk factor and therapeutic management of coronary patients from 24 European countries K Kotseva, D Wood, D De Bacquer, G De Backer, L Rydén, C Jennings, ... European journal of preventive cardiology 23 (6), 636-648, 2016 | 1233 | 2016 |
| Rivaroxaban with or without aspirin in patients with stable peripheral or carotid artery disease: an international, randomised, double-blind, placebo-controlled trial SS Anand, J Bosch, JW Eikelboom, SJ Connolly, R Diaz, P Widimsky, ... The Lancet 391 (10117), 219-229, 2018 | 843 | 2018 |
| Efficacy of telemedical interventional management in patients with heart failure (TIM-HF2): a randomised, controlled, parallel-group, unmasked trial F Koehler, K Koehler, O Deckwart, S Prescher, K Wegscheider, BA Kirwan, ... The Lancet 392 (10152), 1047-1057, 2018 | 527 | 2018 |
| Rivaroxaban with or without aspirin in patients with stable coronary artery disease: an international, randomised, double-blind, placebo-controlled trial SJ Connolly, JW Eikelboom, J Bosch, G Dagenais, L Dyal, F Lanas, ... The Lancet 391 (10117), 205-218, 2018 | 368 | 2018 |
| Complementary and incremental mortality risk prediction by cortisol and aldosterone in chronic heart failure G Güder, J Bauersachs, S Frantz, D Weismann, B Allolio, G Ertl, ... Circulation 115 (13), 1754-1761, 2007 | 363 | 2007 |
| Low-gradient aortic valve stenosis: myocardial fibrosis and its influence on function and outcome S Herrmann, S Störk, M Niemann, V Lange, JM Strotmann, S Frantz, ... Journal of the American College of Cardiology 58 (4), 402-412, 2011 | 352 | 2011 |
| Safety of proton pump inhibitors based on a large, multi-year, randomized trial of patients receiving rivaroxaban or aspirin P Moayyedi, JW Eikelboom, J Bosch, SJ Connolly, L Dyal, ... Gastroenterology 157 (3), 682-691. e2, 2019 | 348 | 2019 |
| The variation of morphological and functional cardiac manifestation in Fabry disease: potential implications for the time course of the disease F Weidemann, F Breunig, M Beer, J Sandstede, S Störk, W Voelker, G Ertl, ... European heart journal 26 (12), 1221-1227, 2005 | 294 | 2005 |
| Carotid artery plaque burden, stiffness, and mortality risk in elderly men: a prospective, population-based cohort study S Störk, AW van den Beld, C von Schacky, CE Angermann, ... Circulation 110 (3), 344-348, 2004 | 279 | 2004 |
| Mode of action and effects of standardized collaborative disease management on mortality and morbidity in patients with systolic heart failure: the Interdisciplinary Network … CE Angermann, S Störk, G Gelbrich, H Faller, R Jahns, S Frantz, ... Circulation: Heart Failure 5 (1), 25-35, 2012 | 274 | 2012 |
| Effect of escitalopram on all-cause mortality and hospitalization in patients with heart failure and depression: the MOOD-HF randomized clinical trial CE Angermann, G Gelbrich, S Störk, H Gunold, F Edelmann, R Wachter, ... Jama 315 (24), 2683-2693, 2016 | 254 | 2016 |
| Heart failure in chronic kidney disease: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference AA House, C Wanner, MJ Sarnak, IL Piña, CW McIntyre, P Komenda, ... Kidney international 95 (6), 1304-1317, 2019 | 251 | 2019 |
| Management of dyslipidaemia in patients with coronary heart disease: results from the ESC-EORP EUROASPIRE V survey in 27 countries G De Backer, P Jankowski, K Kotseva, E Mirrakhimov, Ž Reiner, L Ryden, ... Atherosclerosis 285, 135-146, 2019 | 244 | 2019 |
| Long‐term outcome of enzyme‐replacement therapy in advanced F abry disease: evidence for disease progression towards serious complications F Weidemann, M Niemann, S Störk, F Breunig, M Beer, C Sommer, ... Journal of internal medicine 274 (4), 331-341, 2013 | 225 | 2013 |
| Copeptin in the differential diagnosis of the polydipsia-polyuria syndrome—revisiting the direct and indirect water deprivation tests W Fenske, M Quinkler, D Lorenz, K Zopf, U Haagen, J Papassotiriou, ... The Journal of Clinical Endocrinology & Metabolism 96 (5), 1506-1515, 2011 | 225 | 2011 |
| GOLD or lower limit of normal definition? A comparison with expert-based diagnosis of chronic obstructive pulmonary disease in a prospective cohort-study G Güder, S Brenner, CE Angermann, G Ertl, M Held, AP Sachs, ... Respiratory research 13, 1-9, 2012 | 206 | 2012 |
| Rationale, design and baseline characteristics of participants in the cardiovascular outcomes for people using anticoagulation strategies (COMPASS) trial J Bosch, JW Eikelboom, SJ Connolly, NC Bruns, V Lanius, F Yuan, ... Canadian Journal of Cardiology 33 (8), 1027-1035, 2017 | 177 | 2017 |
| Effect of combined systolic and diastolic functional parameter assessment for differentiation of cardiac amyloidosis from other causes of concentric left ventricular hypertrophy D Liu, K Hu, M Niemann, S Herrmann, M Cikes, S Störk, PD Gaudron, ... Circulation: Cardiovascular Imaging 6 (6), 1066-1072, 2013 | 174 | 2013 |
| Gene mutations versus clinically relevant phenotypes: lyso-Gb3 defines Fabry disease M Niemann, A Rolfs, S Störk, B Bijnens, F Breunig, M Beer, G Ertl, ... Circulation: Cardiovascular Genetics 7 (1), 8-16, 2014 | 170 | 2014 |
Christiane AngermannComprehensive Heart Failure Center Würzburg在 ukw.de 的电子邮件经过验证
